Diffusion-weighted MRI as a biomarker for treatment response in glioma.

Diffusion-weighted imaging (DWI) is a powerful MRI method, which probes abnormalities of tissue structure by detecting microscopic changes in water mobility at a cellular level beyond what is available with other imaging techniques. Accordingly, DWI has the potential to identify pathology before gross anatomic changes are evident on standard anatomical brain images. These features of tissue characterization and earlier detection are what make DWI particularly appealing for the evaluation of gliomas and the newer therapies where standard anatomical imaging is proving insufficient. This article focuses on the basic principles and applications of DWI, and its derived parameter, the apparent diffusion coefficient, for the purposes of diagnosis and evaluation of glioma, especially in the context of monitoring response to therapy.

[1]  A. Sorensen,et al.  Diffusion tensor magnetic resonance imaging of brain tumors. , 2006, Magnetic resonance imaging clinics of North America.

[2]  C. Metreweli,et al.  Diffusion MR imaging in glioma: does it have any role in the pre-operation determination of grading of glioma? , 2002, Clinical radiology.

[3]  Frederik Wenz,et al.  Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy , 2009, Journal of Cancer Research and Clinical Oncology.

[4]  C. Thieke,et al.  Diffusion-weighted imaging-based probabilistic segmentation of high- and low-proliferative areas in high-grade gliomas , 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

[5]  J. Henson,et al.  Brain Tumor Imaging in Clinical Trials , 2008, American Journal of Neuroradiology.

[6]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[7]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J E Heiserman,et al.  Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.

[9]  C. Meyer,et al.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Bradford A Moffat,et al.  The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. , 2006, Neoplasia.

[11]  Timothy D Johnson,et al.  Intravoxel water diffusion heterogeneity imaging of human high‐grade gliomas , 2009, NMR in biomedicine.

[12]  Albert Lai,et al.  Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab , 2011, Journal of Neuro-Oncology.

[13]  Pieter Wesseling,et al.  Diffuse glioma growth: a guerilla war , 2007, Acta Neuropathologica.

[14]  M. Westphal,et al.  Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Christopher Nimsky,et al.  Detection of tumour invasion into the pyramidal tract in glioma patients with sensorimotor deficits by correlation of 18F-fluoroethyl-L-tyrosine PET and magnetic resonance diffusion tensor imaging , 2009, Acta Neurochirurgica.

[16]  Ferenc A Jolesz,et al.  High B‐value apparent diffusion‐weighted images from CURVE‐ball DTI , 2009, Journal of magnetic resonance imaging : JMRI.

[17]  T. Cloughesy,et al.  Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[18]  L G Nyúl,et al.  On standardizing the MR image intensity scale , 1999, Magnetic resonance in medicine.

[19]  Toshihiro Kumabe,et al.  Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. , 2006, Radiology.

[20]  T. Mikkelsen,et al.  DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma , 2012, PloS one.

[21]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[22]  C. Decaestecker,et al.  Apparent Diffusion Coefficient and Cerebral Blood Volume in Brain Gliomas: Relation to Tumor Cell Density and Tumor Microvessel Density Based on Stereotactic Biopsies , 2008, American Journal of Neuroradiology.

[23]  K. Schmainda,et al.  Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter‐ and intrapatient comparisons , 2010, Magnetic resonance in medicine.

[24]  Bradford A Moffat,et al.  Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Wade M Mueller,et al.  The Role of Diffusion Tensor Imaging in Establishing the Proximity of Tumor Borders to Functional Brain Systems: Implications for Preoperative Risk Assessments and Postoperative Outcomes , 2004, Technology in cancer research & treatment.

[26]  D. Le Bihan,et al.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.

[27]  M. Westphal,et al.  Invasion as limitation to anti-angiogenic glioma therapy. , 2003, Acta neurochirurgica. Supplement.

[28]  A. Maia,et al.  MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. , 2005, AJNR. American journal of neuroradiology.

[29]  T L Chenevert,et al.  Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Yi Yan,et al.  Quantitative analysis of glioma cell invasion by diffusion tensor imaging , 2010, Journal of Clinical Neuroscience.

[31]  P. Gutin,et al.  Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma , 2011, American Journal of Neuroradiology.

[32]  H. Lanfermann,et al.  Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences. , 2010, Radiology.

[33]  L. Deangelis,et al.  Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.

[34]  J. Hyde,et al.  Intravoxel distribution of DWI decay rates reveals C6 glioma invasion in rat brain , 2004, Magnetic resonance in medicine.

[35]  T. Hirai,et al.  Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. , 2006, AJNR. American journal of neuroradiology.

[36]  D. Norris,et al.  Biexponential diffusion attenuation in various states of brain tissue: Implications for diffusion‐weighted imaging , 1996, Magnetic resonance in medicine.

[37]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B A Kall,et al.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. , 1987, Journal of neurosurgery.

[39]  R. Fulbright,et al.  Diffusion MRI in the early diagnosis of malignant glioma , 2007, Journal of Neuro-Oncology.

[40]  P. LaViolette,et al.  Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas , 2011, Journal of Neuro-Oncology.

[41]  Derek K. Jones,et al.  Diffusion‐tensor MRI: theory, experimental design and data analysis – a technical review , 2002 .

[42]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[43]  Jayaram K. Udupa,et al.  New variants of a method of MRI scale standardization , 2000, IEEE Transactions on Medical Imaging.

[44]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[45]  D. LeBihan.  IVIM method measures diffusion and perfusion. , 1990, Diagnostic imaging.

[46]  Bram Stieltjes,et al.  Toward an optimal distribution of b values for intravoxel incoherent motion imaging. , 2011, Magnetic resonance imaging.

[47]  J. Ferda,et al.  Diffusion tensor magnetic resonance imaging of glial brain tumors. , 2010, European journal of radiology.

[48]  O. G. Dodge,et al.  Histological Typing of tumours of the Central Nervous System , 1981, British Journal of Cancer.

[49]  P. LaViolette,et al.  Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity , 2010, Journal of magnetic resonance imaging : JMRI.